Skip to content

US · WST · MEDICAL - INSTRUMENTS & SUPPLIES

West Pharmaceutical Services, Inc. (WST) intrinsic value and stock valuation

$390.30as of 2026-11-21 · Mkt cap 24.92B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

West Pharmaceutical Services, Inc. DCF and intrinsic value

InvestorsCraft values WST with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from WST’s statements →

West Pharmaceutical Services, Inc. Graham Number

Graham Number: $82.15d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Exton, PA 19341-1147 westpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.07B+7.4% 5y CAGRd
20112025
Net income
$493.7M+7.4% 5y CAGRd
20112025
Free cash flow
$468.9M+9.5% 5y CAGRd
20112025
Total equity
$3.18B+11.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.07B$2.89B$2.95B$2.89B$2.83B
Operating income$617.4M$594.6M$710.9M$763.5M$758.7M
Net income$493.7M$492.7M$593.4M$585.9M$661.8M
EPSd$6.79M$6.69M$7.88M$7.73M$8.67M
Operating cash flow$754.8M$653.4M$776.5M$724M$584M
Capital expenditure-$-285.9M-$-377M-$-362M-$-284.6M-$-253.4M
Free cash flow$468.9M$276.4M$414.5M$439.4M$330.6M
Total assets$4.27B$3.64B$3.83B$3.62B$3.31B
Total debt$416.7M$305.3M$309M$317.9M$325.3M
Net debt-$-374.6M-$-179.3M-$-544.9M-$-576.4M-$-437.3M
Total equity$3.18B$2.68B$2.88B$2.68B$2.34B
Cash and short-term investments$791.3M$484.6M$853.9M$894.3M$762.6M
Income statement
20252024202320222021
Revenue$3.07B$2.89B$2.95B$2.89B$2.83B
Cost of revenue$1.97B$1.89B$1.82B$1.75B$1.66B
Gross profit$1.1B$1B$1.13B$1.14B$1.17B
Research and development expenses$74.3M$69.1M$68.4M$58.5M$52.8M
Selling, general and administrative expenses$393.1M$338.5M$353.4M$316.9M$361.9M
Other expenses$18.5M$0.00$0.00$0.00$0.00
Operating expenses$485.9M$407.6M$421.8M$375.4M$414.7M
Cost and expenses$2.46B$2.3B$2.24B$2.12B$2.07B
Interest income$17.7M$19.6M$28M$5.1M$1M
Interest expense$600K$2.9M$8.8M$7.6M$8.5M
Depreciation and amortization$124.4M$155.4M$137.3M$120.6M$122.3M
Ebitda$723.6M$743.8M$844.1M$808.1M$879.7M
Operating income$617.4M$594.6M$710.9M$763.5M$758.7M
Total other income/expenses, net-$-2.1M$5.6M$4.8M-$-62.9M$10.3M
Income before tax$615.3M$600.2M$715.7M$700.6M$769M
Income tax expense$121.6M$107.5M$122.3M$114.7M$107.2M
Net income$493.7M$492.7M$593.4M$585.9M$661.8M
Weighted average shares outstanding$72.3M$73M$74.3M$74.4M$74.4M
Weighted average diluted shares outstanding$72.7M$73.7M$75.3M$75.8M$76.3M
Balance sheet
20252024202320222021
Cash and short-term investments$791.3M$484.6M$853.9M$894.3M$762.6M
Net receivables$574.4M$552.5M$512M$507.4M$489M
Inventory$443.9M$377M$434.7M$414.8M$378.4M
Total current assets$1.98B$1.54B$1.94B$1.92B$1.74B
Property, plant and equipment, net$1.84B$1.69B$1.51B$1.26B$1.13B
Goodwill and intangible assets$117.7M$116.9M$123.6M$125.7M$132.9M
Long-term investments$212.3M$202.1M$210M$204.9M$207.7M
Total non-current assets$2.29B$2.11B$1.89B$1.7B$1.57B
Total assets$4.27B$3.64B$3.83B$3.62B$3.31B
Accounts payable$253.7M$239.3M$242.4M$215.4M$232.2M
Short-term debt$22.7M$18.8M$151.7M$18.2M$53.5M
Deferred revenue$0.00$49.6M$41.7M$57.3M$48.7M
Total current liabilities$654.9M$550.4M$671.8M$519M$594.1M
Long-term debt$394M$286.5M$157.3M$299.7M$271.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$439.1M$410.7M$276.7M$412.9M$384.3M
Capital lease obligations$95.6M$83.9M$102.2M$109M$72.3M
Total liabilities$1.09B$961.1M$948.5M$931.9M$978.4M
Common stock$18.8M$18.8M$18.8M$18.8M$18.8M
Retained earnings$4.37B$3.96B$3.52B$2.99B$2.46B
Accumulated other comprehensive income (loss)-$-105.5M-$-258.1M-$-143.8M-$-183M-$-159.6M
Total equity$3.18B$2.68B$2.88B$2.68B$2.34B
Total investments$212.3M$202.1M$210M$204.9M$207.7M
Total debt$416.7M$305.3M$309M$317.9M$325.3M
Net debt-$-374.6M-$-179.3M-$-544.9M-$-576.4M-$-437.3M
Cash flow statement
20252024202320222021
Net income$493.7M$492.7M$593.4M$585.9M$661.8M
Depreciation and amortization$168.6M$155.4M$137.3M$120.6M$122.3M
Stock-based compensation$23.8M$18.7M$23.3M$23.7M$37.5M
Change in working capital$79.8M$2.9M-$-20.4M-$-15M-$-193.8M
Accounts receivable$6.9M-$-58.8M$4M-$-35.6M-$-123.5M
Inventory-$-62.8M$42M-$-13.5M-$-49.8M-$-86.5M
Accounts payable$17.9M$2.9M$4.4M-$-2.8M$16.8M
Net cash provided by operating activities$754.8M$653.4M$776.5M$724M$584M
Investments in property, plant and equipment-$-285.9M-$-377M-$-362M-$-284.6M-$-253.4M
Acquisitions, net$0.00$0.00$0.00$0.00-$-2.2M
Net cash used for investing activities-$-285.9M-$-378.7M-$-368.7M-$-288.2M-$-253.1M
Common stock issued$18.2M$0.00$0.00$0.00$0.00
Common stock repurchased-$-134M-$-566.6M-$-451.2M-$-222.2M-$-151.9M
Dividends paid-$-61.2M-$-59.1M-$-57M-$-54.1M-$-51.1M
Net cash used for financing activities-$-185.1M-$-622.6M-$-459.6M-$-293.6M-$-168.1M
Net change in cash$306.7M-$-369.3M-$-40.4M$131.7M$147.1M
Cash at end of period$791.3M$484.6M$853.9M$894.3M$762.6M
Operating cash flow$754.8M$653.4M$776.5M$724M$584M
Capital expenditure-$-285.9M-$-377M-$-362M-$-284.6M-$-253.4M
Free cash flow$468.9M$276.4M$414.5M$439.4M$330.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About West Pharmaceutical Services, Inc.

        West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

        CEO
        Eric Green
        Employees
        10.8K
        Beta
        1.16

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of West Pharmaceutical Services, Inc. (WST)?

        West Pharmaceutical Services, Inc. (WST) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is WST undervalued?

        WST trades at a price of $390.30 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.